Looking for new frontiers in atrial fibrillation ablation. A remaining challenge for health care | Revista Portuguesa de Cardiologia
Pesquisa avançada
Partilhar
COVID-19
Métricas
Corpo Editorial
Publique nesta revista
  • Guia para autores
  • Envio de manuscrito
  • Ética na publicação
  • Contactar
  • Estatuto editorial
Partilhar
Novembro 2017 Looking for new frontiers in atrial fibrillation ablation. A remaining challenge for...
    Revista Portuguesa de Cardiologia
    ISSN: 0870-2551

    A Revista Portuguesa de Cardiologia, órgão oficial da Sociedade Portuguesa de Cardiologia, foi fundada em 1982 com o objetivo de informar e formar os cardiologistas portugueses através da publicação de artigos cientí­ficos na área da arritmologia, cirurgia cardí­aca, cuidados intensivos, doença coronária, ecocardiografia, electrofisiologia, hipertensão arterial, insuficiência cardíaca, métodos de imagem entre outros. Trata-se duma revista mensal de elevada qualidade cientí­fica e gráfica, publicada em português e em inglês desde 1999 o que permitiu a sua larga projeção no estrangeiro. É distribuída a todos os sócios da Sociedade Portuguesa de Cardiologia, da Sociedade de Medicina Interna, da Sociedade de Portuguesa de Pneumologia e da Sociedade de Cirurgia Cardiotorácica, bem como a cardiologistas estrangeiros de renome internacional e a quase todas as sociedades congéneres do mundo. É referenciada desde 1987 na Medline e posteriormente no Índex Copernicius.

    Ver mais

    Indexada em:

    Index Medicus/Medline, Science Citation Index Expanded/Journal of Citation Reports, Scopus

    Ver mais

    Siga-nos:

    Fator de impacto

    O fator de impacto mede o número médio de citações recebidas em um ano por trabalhos publicados na revista durante os dois anos anteriores.

    © Clarivate Analytics, Journal Citation Reports 2021

    Ver mais
    Fator de impacto 2020
    1,374
    Citescore

    O CiteScore mede as citações médias recebidas por documento publicado. Mais informação

    Ver mais
    Citescore 2019
    1,4
    SJR

    SJR é uma métrica de prestígio baseada na idéia de que todas as citações não são iguais. SJR utiliza um algoritmo similar ao page rank do Google; é uma medida quantitativa e qualitativa ao impacto de uma publicação.

    Ver mais
    SJR 2019
    0,23
    SNIP

    SNIP permite comparar o impacto de revistas de diferentes campos temáticos, corrigindo as diferenças na probabilidade de ser citado que existe entre revistas de distintas matérias.

    Ver mais
    SNIP 2019
    0,423
    Ver mais metricas
    Acesso aberto
    Ocultar
    Informação da revista
    Artigo anterior | Artigo seguinte
    Vol. 36. Núm. S1.
    Páginas 1-2 (Novembro 2017)
    Partilhar
    Partilhar
    Imprimir
    Baixar PDF
    Mais opções do artigo
    ePub
    Estatísticas
    Vol. 36. Núm. S1.
    Páginas 1-2 (Novembro 2017)
    Point of view
    DOI: 10.1016/j.repc.2017.09.012
    Open Access
    Looking for new frontiers in atrial fibrillation ablation. A remaining challenge for health care
    Visitas
    ...
    Baixar PDF
    Mário Oliveiraa,b
    a Hospital Santa Marta, Lisbon, Portugal
    b Institute of Physiology and Cardiovascular Center, University of Lisbon, Faculty of Medicine of Lisbon, Lisbon, Portugal
    Este item recebeu
    ...
    Visitas
    (Atualização diária de dados)

    Under a Creative Commons license
    Informação do artigo
    Texto Completo
    Bibliografia
    Baixar PDF
    Estatísticas
    Texto Completo

    In the last two decades, several randomized clinical trials have shown superiority of catheter ablation over antiarrhythmic drugs therapy to achieve sinus rhythm and to improve symptoms and quality of life in paroxysmal and persistent atrial fibrillation (AF) patients.1,2 Since the first demonstrations that pulmonary veins isolation (PVI) could prevent AF initiation, catheter ablation of AF has evolved from an experimental procedure to a standard rhythm control strategy for patients with symptomatic recurrent AF, and may be appropriate to perform even as first-line therapy.3 Despite progresses in the management of patients with AF, the prevalence of this arrhythmia in increasing worldwide and it remains one of the major causes of stroke, heart failure and cardiovascular morbidity, representing a substantial health burden for patients and societies.

    Catheter ablation of AF is now commonly used and is increasing markedly as a real clinical option for the treatment of this complex arrhythmia, representing around 30% of all ablations performed in Portugal.4 However, AF recurrence can occur in 20-40% of the patients in the first year, requiring an additional catheter ablation. For persistent AF, the situation seems less clear, as the evidence base is weaker.5 Differences in the success rates are likely related to a more complex substrate in persistent (and long-standing persistent) AF, and with the fact that the electrical, autonomic and structural changes related to the atrial remodeling phenomena promote the maintenance of AF, contributing to the resistance to sinus rhythm conversion and to AF recurrences.6,7 More advanced AF is, therefore, more difficult to treat with simple catheter ablation. Nevertheless, around 40% of the procedures performed are reported to be for patients with persistent type of AF.8 This remind us that the optimal ablation technique is still to be elucidated, particularly for the treatment of persistent AF.

    A lot has changed in AF ablation. Knowledge regarding patients selection and follow-up, new catheters, contact-force tools, 3D mapping systems allowing high-resolution electrical analysis, integrating imaging, type of energy used and different technical approaches have evolved over the past years, reflecting the integration of multidisciplinary input of expert cardiologists, cardiac surgeons, electrophysiologists and engineering teams. However, this is a complex intervention with potential major complications and with risk of arrhythmia recurrences, frequently occurring in subjects with PV electrical reconnection.9 Therefore, there is consensus among experts that all patients undergoing AF ablation should be seen in follow-up regularly after the ablation procedure in order to recognize potential complications and optimize outcome results.10

    Looking to the future is something that can be seen in the long journey of those who always keep trying to find the right pathway. This special edition of the Portuguese Journal of Cardiology marks the first Portuguese 20 years of AF ablation based on PV isolation,11 and represents a pure exercise of integration, while taking the experience of various specialists which have been contributing to improve the mechanistic understanding, as well as technological advances, in the management of AF.

    Understanding the role of localized sources, like foci and rotational activity, in the maintenance of AF, and mapping it using innovative technologies in order to increase the success of AF ablation, represents a continuous challenge in this field, discussed by Narayan et al., and Carlo Pappone in this issue of the Journal.12,13 Also, different technical approaches may contribute to improve the efficacy and safety of ablation, particularly concerning persistent AF. Therefore, this issue of the Portuguese Journal of Cardiology also includes extensive data about the advantages and drawbacks of cryoballoon ablation,14 substrate modification, based on isolation of atrial fibrotic areas,15 and complete isolation of the left atrial appendage.16 In order to reduce risks of this complex interventional procedure, experienced operators must share their strategies regarding important rules to avoid complications, and, of course, to identify and manage it adequately following AF ablation. Professor Mauricio Scanavacca explores this important subject in an interesting review article.17

    New information is continually generated and published, in accordance with a substantial progress and development in this field. Investigations have clarified several issues, but the complexity of the mechanisms participating in the pathophysiology of AF disease makes this task an extremely difficult challenge to overcome.

    Current medical guidelines recommend catheter ablation as part of the management strategy in patients with AF, being a first option treatment in selected patients.3 Progression from paroxysmal AF to persistent AF appears to be delayed by early PVI. This provides the rationale for the ability to modify the arrhythmogenic substrate of AF and addresses the question of the best timing for ablation in patients with recent paroxysmal episodes.

    Identification of individualized substrate targets, according to different types of AF in specific-patients, and its elimination (or modulation) with the adequate energy source depends on the emerging advanced mapping technique systems and correct interpretation of the atrial electrophysiological information. Clearly, we all need further investigation to find out whether research teams are flowing in the best direction.

    Conflicts of interest

    The author has no conflicts of interest to declare.

    References
    [1]
    C.M. Hanley, D. Esberg, P.R. Kowey.
    Ablation versus drugs: what is the best first-line therapy for paroxysmal atrial fibrillation?.
    Circ Arrhythm Electrophysiol, (2014), pp. 747-754
    [2]
    L.-Z. Shi, R. Heng, S.-M. Liu, et al.
    Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: a meta-analysis of randomized controlled trials.
    Exp Ther Med, 10 (2015), pp. 816-822
    http://dx.doi.org/10.3892/etm.2015.2545 | Medline
    [3]
    P. Kirchhof, S. Benussi, D. Kotecha, et al.
    ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS 2016.
    Eur Heart J, 37 (2016), pp. 2893-2962
    http://dx.doi.org/10.1093/eurheartj/ehw210 | Medline
    [4]
    M. Oliveira, F. Madeira, D. Bonhorst, et al.
    National registry on cardiac electrophysiology.
    Rev Port Cardiol, 33 (2014), pp. 583-589
    http://dx.doi.org/10.1016/j.repc.2014.01.006 | Medline
    [5]
    H.S. Chen, J.M. Wen, S.N. Wu, et al.
    Catheter ablation for paroxysmal and persistent atrial fibrillation.
    Cochrane Database Syst Rev, 18 (2012),
    CD007101
    [6]
    D.M. Muntean, Z. Kohajda, T. Fazekas, et al.
    Atrial remodeling in permanent atrial fibrillation: mechanisms and pharmacological implications.
    J Clin Exp Cardiol, 4 (2013), pp. 273
    http://dx.doi.org/10.4172/2155-9880.1000273
    [7]
    M. Oliveira, N. da Silva, P. Cunha, et al.
    Effects of acute autonomic modulation on atrial conduction delay and local electrograms duration in paroxysmal atrial fibrillation.
    Int J Cardiol, 149 (2011), pp. 290-295
    http://dx.doi.org/10.1016/j.ijcard.2010.02.006 | Medline
    [8]
    R. Cappato, H. Calkins, S.A. Chen, et al.
    Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.
    Circ Arrhythm Electrophysiol, 3 (2010), pp. 32-38
    http://dx.doi.org/10.1161/CIRCEP.109.859116 | Medline
    [9]
    P.B. Nery, D. Belliveau, G.M. Nair, et al.
    Relationship between pulmonary vein reconnection and atrial fibrillation: a systematic review and meta-analysis.
    JACC: Clin Electrophysiol, 2 (2016), pp. 474-483
    [10]
    M.M. Oliveira.
    How to follow atrial fibrillation ablation patients?.
    J Atrial Fibrillation, 7 (2014), pp. 187
    [11]
    P. Adragão, F.P. Machado, C. Aguiar, et al.
    Ablation of atrial fibrillation in mitral valve disease patients: five year follow-up after percutaneous pulmonary vein isolation and mitral balloon valvuloplasty.
    Rev Port Cardiol, 22 (2003), pp. 1025-1036
    Medline
    [12]
    S. Narayan, M. Viswanathan, C. Kowalewski, et al.
    The continuous challenge of AF ablation: from foci to rotational activity.
    Rev Port Cardiol, (2017),
    http://dx.doi.org/10.1016/j.repc.2017.09.007 | Medline
    [13]
    C. Pappone.
    How to map persistent AF and increase efficacy of ablation therapy.
    Rev Port Cardiol, (2017),
    http://dx.doi.org/10.1016/j.repc.2017.09.009 | Medline
    [14]
    S. Boveda.
    Cryoballoon ablation in atrial fibrillation: advantages and drawbacks?.
    Rev Port Cardiol, (2017),
    http://dx.doi.org/10.1016/j.repc.2017.09.008 | Medline
    [15]
    F. Moser, D. Schreiber, A. Rieger, et al.
    Box isolation of fibrotic areas: a substrate modification approach in atrial fibrillation patients.
    Rev Port Cardiol, (2017),
    http://dx.doi.org/10.1016/j.repc.2017.09.010 | Medline
    [16]
    R. Romero, A. Natale, L. Di Biase.
    Atrial fibrillation ablation beyond pulmonary veins: the role of left atrial appendage.
    Rev Port Cardiol, (2017),
    http://dx.doi.org/10.1016/j.repc.2017.09.011 | Medline
    [17]
    M. Scanavacca.
    How to prevent, recognize and manage complications of AF ablation?.
    Rev Port Cardiol, (2017),
    http://dx.doi.org/10.1016/j.repc.2017.09.005 | Medline


    Receba a nossa Newsletter

    Conteúdo especial sobre COVID-19
    • Myocarditis and COVID-19 mRNA vaccination
    • Remote invasive monitoring of pulmonary artery pressures in heart failure patients: Initial experience in Portugal in the context of the Covid-19 pandemic
    • Effects of azithromycin on ventricular repolarization in children with COVID-19
    • ST-elevation myocardial infarction in the Covid-19 pandemic: A step backward in a success story
    Ver mais
    Ferramentas
    • Imprimir
    • Enviar a um amigo
    • Exportar referência
    • CrossMark
    • Mendeley
    • Estatísticas
    Artigos
    recomendados
    Commemorating twenty years since the first catheter¿based...
    Rev Port Cardiol 2017;36 Supl 1:3-5
    Myocarditis and COVID-19 mRNA...
    10.1016/j.repc.2021.08.009
    Successful single shot cryoballoon isolation of the left...
    Rev Port Cardiol. 2022;41:347-8
    Sociedade Portuguesa de Cardiologia
    Publicar em
    Revista Portuguesa de Cardiologia
    • Guia para autores
    • Envio de manuscrito
    • Ética na publicação
    • Contactar
    • Estatuto editorial
    A revista pertence ao Committee on Publication Ethics (COPE) www.publicationethics.org e adere aos seus princípios e procedimentos.

    Ler

    • Antevisão online
    • Número atual
    • Os mais lidos

    Arquivo

    • Arquivo
    • Suplementos

    Publique nesta revista

    • Guia para autores
    • Envio de manuscrito
    • Ética na publicação
    • Contactar
    • Estatuto editorial
    • Corpo Editorial

    Informação legal

    • Autorizações de reprodução
    • Termos e Condições
    • Cláusula de privacidade

    Inscreva-se

    • Alerta por e-mail
    • RSS
    Contactar
    Corpo Editorial
    © Copyright 2022. Sociedade Portuguesa de Cardiologia

    Este site usa cookies. Para rejeitar ou saber mais, visite nossa página Política de Cookies.
    Elsevier España S.L.U. © 2022. Todos los derechos reservados
    Idiomas
    • English
    • Português
    Revista Portuguesa de Cardiologia
    • Número atual
    • Antevisão online
    • Arquivo
    • Suplementos
    • Os mais lidos
    • Open Access
    • Corpo Editorial
    • Publique nesta revista
      • Guia para autores
      • Envio de manuscrito
      • Ética na publicação
      • Contactar
      • Estatuto editorial

    Receba a nossa Newsletter

    Opções de artigo
    • Read in English
    • Baixar PDF
    • Bibliografia
    Ferramentas
    • Imprimir
    • Enviar a um amigo
    • Exportar referência
    • CrossMark
    • Mendeley
    • Estatísticas
    en pt

    Are you a health professional able to prescribe or dispense drugs?

    Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

    Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.